R
Redona Therapeutics
Small molecules that can modulate levels of mirnas by targeting proteins that interact with these mirnas
About Redona Therapeutics
Redona Therapeutics, formerly known as Twentyeight-Seven Therapeutics, is a clinical-stage biotechnology company founded in 2016. The firm is headquartered in Watertown, Massachusetts, and operates within the drug discovery and biotechnology industries. The company was established by a team of prominent scientists with deep expertise in RNA biology and cancer: George Daley, Richard Gregory, Frank Slack, and Piotr Sliz. The leadership team includes President and CEO Kazumi Shiosaki, a seasoned executive with a history of co-founding and leading successful biotech startups like Mitobridge and Epizyme. Shiosaki's experience, which includes a Ph.D. in Synthetic Chemistry from UC Berkeley and roles at Millennium Pharmaceuticals and MPM Capital, is central to the company's strategy of exploring novel areas of biology.
Redona's core business revolves around developing small-molecule drugs that target enzymes responsible for regulating RNA and DNA processes. The company's scientific premise is that the dysregulation of these fundamental cellular mechanisms, such as RNA splicing, stability, and sensing, is a key driver of serious human diseases, including cancer and autoimmune disorders. By creating therapies that modulate these RNA modulating proteins (RMPs), Redona aims to control the expression of oncogenes and other critical disease-related proteins, thereby restoring normal cellular function. This approach is designed to impact multiple hallmarks of a disease simultaneously, offering a potential advantage over therapies that target a single pathway.
The company's revenue model is based on the development and potential commercialization of its therapeutic pipeline, as well as establishing partnerships to explore applications of its technology outside of its primary focus areas. Redona has successfully raised significant capital to fund its research and development efforts, securing a total of $144 million over five funding rounds, including a notable $65 million Series A in 2018. Its investor syndicate includes major players in the life sciences venture capital space, such as MPM Capital, Sofinnova Partners, Novartis Venture Fund, and Johnson & Johnson Innovation. Redona's pipeline includes several programs targeting enzymes like TUT4/7, cGAS, and CLK, which are implicated in various solid tumors and heme malignancies. The company has developed potent and selective inhibitors that have shown promising efficacy in preclinical cancer models and is advancing them toward clinical studies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Aug 2023 | $12M | — | Undisclosed | ↗ |
| SERIES AOther financing | May 2019 | $15M | $60M | Sofinnova Partners · Vertex Holdings · MPM BioImpact · Novartis Venture Fund | — |
Growth signals
Latest recorded traffic for Redona Therapeutics is 4.7K monthly website visits, up 46900% over the last three months. Redona Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Redona Therapeutics in the Cambridge ecosystem
The Redona Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Greylock Partners
Novartis Venture Fund
MPM BioImpact
Astellas Venture
Johnson & Johnson Innovation
Vertex Holdings
Longwood Fund
Sofinnova Partners
Vertex Ventures HC
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Redona Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Redona Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








